Kiniksa Pharmaceuticals International, plc (KNSA) fair value analysis
Nasdaq · Updated 2026-10-19
KNSA price how computed
Forward Fair Value verdict
Fairly valuedKNSA is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $78.59
- Sector
- Healthcare
- 12-month range
- $37.01–$80.92
- Market cap
- $6.13B
- From 52-week high
- -2.9%
- Shares outstanding
- 78M
- Rank in Healthcare by discount to fair value
- #104 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company that develops and commercializes medicines to treat inflammatory and autoimmune diseases. The company operates internationally with operations spanning the United States and other markets.
KNSA currently ranks #104 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $6.13B
- P/E (trailing)
- 81x
- Revenue (TTM)
- $841M
- Net margin
- 9.6%
- EPS (TTM)
- $0.97
- Gross margin
- 54.2%
- Debt / equity
- 0.01
- Revenue growth (3-yr avg)
- 87.8%
- Shares outstanding
- 78M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 47 · neutral
- 50-day average
- $77.84
- 200-day average
- $58.04
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-10-27
- Last 8 quarters vs consensus
- 1 beat, 6 missed
- Quarter by quarter
- 2026-06 ▬ met (0.0%)
2026-03 ▲ beat (+68.8%)
2025-12 ▼ miss (-57.5%)
2025-09 ▼ miss (-37.8%)
2025-06 ▼ miss (-11.5%)
2025-03 ▼ miss (-60.7%)
2024-12 ▼ miss (-700.0%)
2024-09 ▼ miss (-357.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 0 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $98
- Target vs last price
- +24.7%
What our data shows for KNSA
- Our model validated 7 trailing price-to-earnings windows for KNSA, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $37.01–$80.92.
- The 14-day relative strength index sits at a neutral 47.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for KNSA
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the KNSA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — KNSA's sector discount rank improved this week, moving from #71 to #66 among healthcare companies, indicating a modest strengthening of its valuation position relative to peers. The stock remains fairly valued according to current assessment.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — KNSA is a healthcare sector company currently assessed as fairly valued. The company's 50/200-day trend state shifted from mixed to uptrend this week, while its sector discount rank moved from number 58 to number 72, indicating a relative change in valuation positioning compared to other healthcare stocks.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — KNSA's trend indicators shifted this week as the stock transitioned from an uptrend to a mixed state in its 50/200-day analysis. The company's sector discount ranking improved from 68th to 58th place within the Healthcare sector, suggesting it is trading at a relatively more attractive valuation compared to its peers. The stock maintains a fairly valued assessment according to current valuation metrics.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is KNSA stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), KNSA is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is KNSA's TickrTrends verdict?
KNSA's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does KNSA compare to other Healthcare stocks?
KNSA ranks #104 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is KNSA overbought or oversold?
KNSA's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does KNSA report earnings next?
KNSA's next earnings report is scheduled for 2026-10-27, per the published earnings calendar.
Does KNSA usually beat earnings estimates?
Over its last 8 reported quarters KNSA beat the consensus estimate 1 times and missed 6 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about KNSA?
Of 8 analysts covering KNSA, 8 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $98 (+24.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
KNSA vs ACHC · KNSA vs DHR · KNSA vs HCA · KNSA vs HCSG · KNSA vs IQV